Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR1 V592M FGFR1 K687E||glioblastoma||predicted - sensitive||Debio 1347||Case Reports/Case Series||Actionable||In a clinical case study, Debio 1347 treatment resulted in a near complete response with a 96.3% maximal tumor reduction after 2 months of therapy in a pediatric patient with spinal cord glioblastoma harboring FGFR1 V592M and FGFR1 K687E, and the response was maintained for 11 months (PMID: 34250399).||34250399|
|FGFR1 V592M FGFR1 K687E||pilomyxoid astrocytoma||predicted - sensitive||Debio 1347||Case Reports/Case Series||Actionable||In a clinical case study, Debio 1347 treatment resulted in a significant clinical improvement and sustained stable disease at 14 months with a 12.2% maximal tumor reduction in a pediatric patient with optic pathway pilomyxoid astrocytoma harboring FGFR1 V592M and FGFR1 K687E (PMID: 34250399).||34250399|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|